Core Viewpoint - Serina Therapeutics has appointed Dr. Joshua Thomas as Vice President and Head of Chemistry to enhance its drug optimization efforts for its lead candidate SER-252, aimed at treating advanced Parkinson's disease using the proprietary POZ Platform technology [1][3]. Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications, utilizing its POZ Platform to improve the efficacy and safety profiles of various therapeutic modalities [4][5]. - The POZ technology is based on a synthetic polymer that allows for better control in drug loading and release rates, addressing limitations of existing drugs [5]. Leadership Appointment - Dr. Joshua Thomas brings over 13 years of experience from Mersana Therapeutics, where he contributed significantly to discovery chemistry and the development of antibody drug conjugate technologies [2][3]. - His expertise includes developing cytotoxic payloads and designing bioconjugation systems, aligning with Serina's strategy to advance its small molecule opportunities [2][3]. Strategic Goals - The company aims to expand the POZ platform into new therapeutic modalities and enhance its drug development capabilities [3]. - Dr. Thomas expressed enthusiasm about leading the chemistry efforts to deliver patient-focused therapies, highlighting the strength of Serina's scientific foundation [4]. Product Development - SER-252, an investigational apomorphine therapy developed with the POZ platform, is designed to provide continuous dopaminergic stimulation, potentially reducing motor complications in Parkinson's disease [7]. - Preclinical studies suggest SER-252 may offer benefits without skin reactions, with plans to advance to clinical testing in 2025 [7]. Collaborative Efforts - Serina is exploring additional applications of the POZ platform through partnerships, including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery formulations [6].